Adalimumab

Lilly wins EU approval for psoriatic arthritis mAb

30-Jan-2018 By Staff Reporter

Eli Lilly’s arthritis monoclonal antibody Taltz (ixekizumab) has been approved for a second indication in Europe.

Room for another: Sandoz files Humira biosimilar in US

16-Jan-2018 By Dan Stanton

“There is room in most markets for a number of competitors” says Novartis as it submits its biosimilar adalimumab for review.

Samsung Bioepis ups EU presence with Humira biosimilar approval

25-Aug-2017 By Dan Stanton

Imraldi becomes the second version of AbbVie’s best-selling biologic Humira (adalimumab) to be approved and the fourth biosimilar success for Samsung Bioepis in Europe.

Samsung Bioepis teams with Takeda to take first steps into novel biologics space

22-Aug-2017 By Dan Stanton

Samsung Bioepis says it will continue focusing on biosimilars as it ventures into the innovative biologics space through a partnership with Takeda.

EMA committee gives Samsung Bioepis nod for Humira biosimilar Imraldi

23-Jun-2017 By Dan Stanton

The EMA has recommended the approval of Samsung Bioepis’ adalimumab biosimilar, placing the firm on the brink of having three anti-TNF inhibitors in Europe.

Amgen's two-brand strategy? EU thumbs up for Humira biosimilar duo

31-Jan-2017 By Dan Stanton

The EMA has recommended approval of two versions of AbbVie’s bestselling biologic Humira (adalimumab), both made by Amgen.

Pfenex, Pfizer and Sandoz hail US FDA interchangeability guidelines

18-Jan-2017 By Dan Stanton

A clear interchangeability pathway is essential for the US biosimilar market say developers as they begin reviewing the much-welcomed draft FDA guidance.

Humira biosimilar developers: can you find who's taking on AbbVie?

23-Dec-2016 By Dan Stanton

Over 30 companies are looking to compete against Abbvie in the adalimumab space. Can you find them all in our word search?

CPhI South Korea

Korea positioned to be global biopharma powerhouse, says industry association

25-Aug-2016 By Dan Stanton

Stem cells and biosimilars are driving the Korean pharma market, according to the country’s Biomedicine Industry Association KoBIA.

Biosimilar uptake driven by a country’s healthcare system, says IMS Health

13-May-2016 By Dan Stanton

Countries with a tender-based healthcare system are adopting biosimilars at a far greater rate than those without, according to IMS Health.

Biologic makers looking to delivery devices to gain competitive edge, Bespak

05-Jan-2016 By Dan Stanton

Having a proactive approach to delivery technologies will give pharma firms a competitive edge against biosimilars and biobetters, according to device maker Bespak.

Korea Enbrel biosimilar approval a milestone for Merck and Samsung JV

11-Sep-2015 By Dan Stanton

A copycat version of Amgen’s Enbrel has been approved in Korea, marking the first regulatory success for Merck & Co and Samsung Bioepis' biosimilar joint venture.

Lupin launches JV with Yoshindo to develop biosimilars for Japan

30-Apr-2014 By Zachary Brennan

In an attempt to corner the Japanese biosimilar market, Pharma companies Lupin and Yoshindo are creating a new entity, known as YL Biologics (YLB).

Baxter spin-off to focus on biosimilars and haematology growth

28-Mar-2014 By Dan Stanton

The spin-off of Baxter’s biopharmaceutical business will be driven by haematology and biosimilar growth opportunities, the company says.

Alexion quizzed over Soliris' $567,000 price by NICE

05-Mar-2014 By Dan Stanton

NICE has asked Alexion Pharmaceuticals to explain why its drug Soliris costs over thirty times that of other monoclonal antibodies.